Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ADAPT Data Linking Naproxen To Heart Risk Is “Not Reliable” – Nissen

This article was originally published in The Tan Sheet

Executive Summary

The premature halting of the ADAPT trial and subsequent safety concerns for naproxen were "inappropriate and reflected faulty logic," according to Cleveland Clinic cardiologist Steven Nissen, MD

You may also be interested in...

Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review

The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12

Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial

The OTC industry is taking a wait-and-see approach regarding concerns about cardiovascular risks of naproxen (Bayer's Aleve) and other older NSAIDs rising in the wake of COX-2-related safety issues

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts